Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
percutaneous coronary intervention · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| TAXUS Express | EXPERIMENTAL | - |
| Express Bare | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| percutaneous coronary intervention | DEVICE | - |
Inclusion Criteria: 1. Patient is \> or = 18 years old 2. Eligible for percutaneous coronary intervention (PCI) 3. Documented stable angina pectoris (Canadian Cardiovascular Society Classification \[CCS\] 1, 2, 3, or 4) or unstable angina pectoris with documented ischemia (Braunwald Class IB-C, IIB...
Percutaneous coronary intervention is a procedure used to treat coronary artery disease. It involves opening narrowed or blocked coronary arteries to restore blood flow to the heart muscle. In the context of the TAXUS IV-SR trial, it was performed using a paclitaxel-eluting stent to treat de novo coronary lesions.
Boston Scientific Corporation (ticker: BSX) is the developer of the percutaneous coronary intervention product evaluated in the TAXUS IV-SR trial. The company conducted a Phase 2 clinical study of this intervention in patients with coronary artery disease.
Percutaneous coronary intervention is in Phase 2 clinical development. The TAXUS IV-SR trial, which tested a single paclitaxel-eluting stent, was a Phase 2 study. The trial has been completed, and the intervention remains investigational for coronary artery disease.
Percutaneous coronary intervention was studied in the TAXUS IV-SR trial (NCT00292474), a Phase 2, randomized, double-blind, placebo-controlled study. The trial enrolled 1,326 participants with coronary artery disease in the United States and has been completed.
The data provided does not indicate that percutaneous coronary intervention is FDA approved. It is an investigational intervention that was evaluated in a completed Phase 2 clinical trial. No approval status is stated, so it should be considered still in clinical development.
Percutaneous coronary intervention is a procedure, and the TAXUS IV-SR trial used a paclitaxel-eluting stent as the intervention. The trial title specifies 'Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent,' indicating that the stent is the device used within the procedure.